Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00146068 · ClinicalTrials.gov registry record · Phase 4
EARLY IFNB-1a and Simvastatin Combination Therapy in Clinically Isolated Syndrome Suggestive of Multiple Sclerosis
A Phase 4 study, sponsored by University of North Carolina.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT00146068 is a Phase 4 study that has completed, run by University of North Carolina. The registered enrollment target is 30 participants.
The verdict
NCT00146068, a Phase 4 study, has completed, sponsored by University of North Carolina.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety, tolerability and efficacy of a combination therapy interferon beta-1a(Avonex) plus simvastatin (Zocor) vs. interferon beta-1a plus placebo in patients with clinically isolated syndrome suggestive of Multiple Sclerosis.
Interventions
- DRUG Avonex/Zocor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2004-09 |
| Est. Completion | 2007-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00146068
The ClinicalTrials.gov registry entry for NCT00146068 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Avonex/Zocor is the first listed.
NCT00146068 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00146068 about?
NCT00146068 is a clinical study titled "EARLY IFNB-1a and Simvastatin Combination Therapy in Clinically Isolated Syndrome Suggestive of Multiple Sclerosis". The purpose of this study is to determine the safety, tolerability and efficacy of a combination therapy interferon beta-1a(Avonex) plus simvastatin (Zocor) vs. interferon beta-1a plus placebo in patients with clinically isolated syndrome suggestive of Multiple Sclerosis.
What is the current status of trial NCT00146068?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2004-09. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00146068?
The interventions under investigation include: Avonex/Zocor (DRUG).
Who is sponsoring clinical trial NCT00146068?
This trial is sponsored by University of North Carolina, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.